Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

Related Articles by Review for PubMed (Select 21178005)

1.

Tumor-associated a2 vacuolar ATPase acts as a key mediator of cancer-related inflammation by inducing pro-tumorigenic properties in monocytes.

Kwong C, Gilman-Sachs A, Beaman K.

J Immunol. 2011 Feb 1;186(3):1781-9. doi: 10.4049/jimmunol.1002998. Epub 2010 Dec 22.

2.

Interleukin-18.

Dinarello CA.

Methods. 1999 Sep;19(1):121-32. Review.

PMID:
10525448
3.

Cooperation of liver cells in health and disease.

Kmieć Z.

Adv Anat Embryol Cell Biol. 2001;161:III-XIII, 1-151. Review.

PMID:
11729749
4.

VEGF as a mediator of tumor-associated immunodeficiency.

Ohm JE, Carbone DP.

Immunol Res. 2001;23(2-3):263-72. Review.

PMID:
11444391
5.

Vacuolar H(+)-ATPase: functional mechanisms and potential as a target for cancer chemotherapy.

Torigoe T, Izumi H, Ise T, Murakami T, Uramoto H, Ishiguchi H, Yoshida Y, Tanabe M, Nomoto M, Kohno K.

Anticancer Drugs. 2002 Mar;13(3):237-43. Review.

PMID:
11984067
6.

Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators.

Ben-Baruch A.

Semin Cancer Biol. 2006 Feb;16(1):38-52. Epub 2005 Aug 31. Review.

PMID:
16139507
7.

NF-kappaB: key mediator of inflammation-associated cancer.

Ditsworth D, Zong WX.

Cancer Biol Ther. 2004 Dec;3(12):1214-6. Epub 2004 Dec 15. Review.

8.

Plasmalemmal vacuolar-type H+-ATPase in cancer biology.

Sennoune SR, Luo D, Martínez-Zaguilán R.

Cell Biochem Biophys. 2004;40(2):185-206. Review.

PMID:
15054222
9.

Plasmalemmal vacuolar H+-ATPases in angiogenesis, diabetes and cancer.

Sennoune SR, Martinez-Zaguilan R.

J Bioenerg Biomembr. 2007 Dec;39(5-6):427-33. Review.

PMID:
18058006
10.

Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy?

Apte RN, Voronov E.

Immunol Rev. 2008 Apr;222:222-41. doi: 10.1111/j.1600-065X.2008.00615.x. Review.

PMID:
18364005
11.

Role of inflammatory mediators in angiogenesis.

Naldini A, Carraro F.

Curr Drug Targets Inflamm Allergy. 2005 Feb;4(1):3-8. Review.

PMID:
15720228
12.

Differentiation and gene expression profile of tumor-associated macrophages.

Schmieder A, Michel J, Schönhaar K, Goerdt S, Schledzewski K.

Semin Cancer Biol. 2012 Aug;22(4):289-97. doi: 10.1016/j.semcancer.2012.02.002. Epub 2012 Feb 13. Review.

PMID:
22349514
13.

Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site.

Laoui D, Van Overmeire E, Movahedi K, Van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, De Baetselier P, Van Ginderachter JA.

Immunobiology. 2011 Nov;216(11):1192-202. doi: 10.1016/j.imbio.2011.06.007. Epub 2011 Jun 30. Review.

PMID:
21803441
14.

Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions.

Wang HW, Joyce JA.

Cell Cycle. 2010 Dec 15;9(24):4824-35. Epub 2010 Dec 15. Review.

15.

The role of inflammation in lung cancer.

Gomes M, Teixeira AL, Coelho A, Araújo A, Medeiros R.

Adv Exp Med Biol. 2014;816:1-23. doi: 10.1007/978-3-0348-0837-8_1. Review.

PMID:
24818717
16.

Ectonucleotidases in tumor cells and tumor-associated immune cells: an overview.

Bergamin LS, Braganhol E, Zanin RF, Edelweiss MI, Battastini AM.

J Biomed Biotechnol. 2012;2012:959848. doi: 10.1155/2012/959848. Epub 2012 Oct 14. Review.

17.

Cancer-related inflammation: common themes and therapeutic opportunities.

Balkwill FR, Mantovani A.

Semin Cancer Biol. 2012 Feb;22(1):33-40. doi: 10.1016/j.semcancer.2011.12.005. Epub 2011 Dec 24. Review.

PMID:
22210179
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk